{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:56:49Z","timestamp":1791633409128,"version":"4.3.4"},"reference-count":100,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":613,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005881","name":"Hemostasis and Thrombosis Research Society","doi-asserted-by":"publisher","award":["Mentored Research Award"],"award-info":[{"award-number":["Mentored Research Award"]}],"id":[{"id":"10.13039\/100005881","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["K08HL138142"],"award-info":[{"award-number":["K08HL138142"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["K99HL150594"],"award-info":[{"award-number":["K99HL150594"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL133113"],"award-info":[{"award-number":["R01HL133113"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1111\/jth.15082","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T16:07:41Z","timestamp":1599062861000},"page":"607-616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications"],"prefix":"10.1016","volume":"19","author":[{"given":"Shruti","family":"Chaturvedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan M.","family":"Braunstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Brodsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1111\/jth.15082_bb0010","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1111\/jth.15082_bb0015","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/blood-2007-01-066043","article-title":"Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study","volume":"110","author":"Galli","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1111\/jth.15082_bb0020","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1073\/pnas.87.11.4120","article-title":"Anti\u2010phospholipid antibodies are directed against a complex antigen that includes a lipid\u2010binding inhibitor of coagulation: beta 2\u2010glycoprotein I (apolipoprotein H)","volume":"87","author":"McNeil","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10.1111\/jth.15082_bb0025","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1182\/blood.V74.7.2426.2426","article-title":"Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant","volume":"74","author":"Marciniak","year":"1989","journal-title":"Blood"},{"issue":"1","key":"10.1111\/jth.15082_bb0030","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2141.2006.06385.x","article-title":"Decreased anticoagulant response to tissue factor pathway inhibitor type 1 in plasmas from patients with lupus anticoagulants","volume":"136","author":"Liestol","year":"2007","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1111\/jth.15082_bb0035","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1182\/blood-2004-05-1708","article-title":"Annexin A2 mediates endothelial cell activation by antiphospholipid\/anti\u2010beta2 glycoprotein I antibodies","volume":"105","author":"Zhang","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1111\/jth.15082_bb0040","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1002\/art.21968","article-title":"Anti\u2010beta2\u2010glycoprotein I antibodies in complex with beta2\u2010glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib\u2010IX\u2010V","volume":"54","author":"Shi","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1111\/jth.15082_bb0045","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1002\/art.22802","article-title":"Anti\u2010beta2\u2010glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts","volume":"56","author":"Sorice","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1111\/jth.15082_bb0050","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1055\/s-0037-1599081","article-title":"Extracellular vesicles in the antiphospholipid syndrome","volume":"44","author":"Chaturvedi","year":"2018","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"10.1111\/jth.15082_bb0055","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/0002-9378(94)90403-0","article-title":"Reduction of annexin\u2010V (placental anticoagulant protein\u2010I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion","volume":"171","author":"Rand","year":"1994","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"10.1111\/jth.15082_bb0060","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1055\/s-0035-1556725","article-title":"Antiphospholipid syndrome\u2010not a noninflammatory disease","volume":"41","author":"de Groot","year":"2015","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"10.1111\/jth.15082_bb0065","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/ncprheum0432","article-title":"The antiphospholipid syndrome as a disorder initiated by inflammation: implications for the therapy of pregnant patients","volume":"3","author":"Salmon","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"7","key":"10.1111\/jth.15082_bb0070","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/art.21157","article-title":"Requirement of activation of complement C3 and C5 for antiphospholipid antibody\u2010mediated thrombophilia","volume":"52","author":"Pierangeli","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"14","key":"10.1111\/jth.15082_bb0075","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1177\/0961203312458839","article-title":"C6 knock\u2010out mice are protected from thrombophilia mediated by antiphospholipid antibodies","volume":"21","author":"Carrera\u2010Marin","year":"2012","journal-title":"Lupus"},{"issue":"7","key":"10.1111\/jth.15082_bb0080","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1182\/blood-2005-03-1319","article-title":"Thrombus formation induced by antibodies to beta2\u2010glycoprotein I is complement dependent and requires a priming factor","volume":"106","author":"Fischetti","year":"2005","journal-title":"Blood"},{"issue":"22","key":"10.1111\/jth.15082_bb0085","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1182\/blood-2013-11-537704","article-title":"A non\u2010complement\u2010fixing antibody to beta2 glycoprotein I as a novel therapy for antiphospholipid syndrome","volume":"123","author":"Agostinis","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1111\/jth.15082_bb0090","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1172\/JCI200318817","article-title":"Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome","volume":"112","author":"Girardi","year":"2003","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1111\/jth.15082_bb0095","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/nm1121","article-title":"Heparin prevents antiphospholipid antibody\u2010induced fetal loss by inhibiting complement activation","volume":"10","author":"Girardi","year":"2004","journal-title":"Nat Med"},{"issue":"7","key":"10.1111\/jth.15082_bb0100","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood-2007-01-070631","article-title":"Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury","volume":"110","author":"Redecha","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1111\/jth.15082_bb0105","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood.2019003863","article-title":"Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS","volume":"135","author":"Chaturvedi","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1111\/jth.15082_bb0110","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/MBC.0000000000000720","article-title":"Complement\u2010coagulation connections","volume":"29","author":"Conway","year":"2018","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"9","key":"10.1111\/jth.15082_bb0115","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1161\/CIRCRESAHA.116.306853","article-title":"Cross talk pathways between coagulation and inflammation","volume":"118","author":"Foley","year":"2016","journal-title":"Circ Res"},{"issue":"5","key":"10.1111\/jth.15082_bb0120","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMc0809959","article-title":"Eculizumab for congenital atypical hemolytic\u2010uremic syndrome","volume":"360","author":"Gruppo","year":"2009","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1111\/jth.15082_bb0125","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1182\/blood-2012-09-311381","article-title":"Thrombosis in paroxysmal nocturnal hemoglobinuria","volume":"121","author":"Hill","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1111\/jth.15082_bb0130","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1326442","article-title":"Local endothelial complement activation reverses endothelial quiescence, enabling T\u2010cell homing, and tumor control during T\u2010cell immunotherapy","volume":"6","author":"Facciabene","year":"2017","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1111\/jth.15082_bb0135","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ekir.2016.08.015","article-title":"Complement activation induces neutrophil adhesion and neutrophil\u2010platelet aggregate formation on vascular endothelial cells","volume":"2","author":"Riedl","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1111\/jth.15082_bb0140","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.kint.2016.03.023","article-title":"Von Willebrand factor regulates complement on endothelial cells","volume":"90","author":"Noone","year":"2016","journal-title":"Kidney Int"},{"issue":"1","key":"10.1111\/jth.15082_bb0145","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00281-011-0280-x","article-title":"Interactions between coagulation and complement\u2013their role in inflammation","volume":"34","author":"Oikonomopoulou","year":"2012","journal-title":"Semin Immunopathol"},{"issue":"7","key":"10.1111\/jth.15082_bb0150","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.4049\/jimmunol.177.7.4794","article-title":"A novel C5a receptor\u2010tissue factor cross\u2010talk in neutrophils links innate immunity to coagulation pathways","volume":"177","author":"Ritis","year":"2006","journal-title":"J Immunol"},{"issue":"15","key":"10.1111\/jth.15082_bb0155","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.1016\/S0021-9258(18)81901-9","article-title":"Complement proteins C5b\u20139 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP\u2010140 to the cell surface","volume":"264","author":"Hattori","year":"1989","journal-title":"J Biol Chem"},{"issue":"24","key":"10.1111\/jth.15082_bb0160","doi-asserted-by":"crossref","first-page":"11907","DOI":"10.1016\/S0021-9258(18)37872-4","article-title":"Complement proteins C5b\u20139 initiate secretion of platelet storage granules without increased binding of fibrinogen or von Willebrand factor to newly expressed cell surface GPIIb\u2010IIIa","volume":"263","author":"Ando","year":"1988","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1111\/jth.15082_bb0165","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/09537100701777311","article-title":"Expression of complement components and inhibitors on platelet microparticles","volume":"19","author":"Yin","year":"2008","journal-title":"Platelets"},{"issue":"10","key":"10.1111\/jth.15082_bb0170","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/CIRCRESAHA.110.233056","article-title":"Microparticles in hemostasis and thrombosis","volume":"108","author":"Owens","year":"2011","journal-title":"Circ Res"},{"issue":"1","key":"10.1111\/jth.15082_bb0175","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1172\/JCI4985","article-title":"In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant","volume":"104","author":"Combes","year":"1999","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1111\/jth.15082_bb0180","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.thromres.2013.11.027","article-title":"Plasma microparticle tissue factor activity in patients with antiphospholipid antibodies with and without clinical complications","volume":"133","author":"Willemze","year":"2014","journal-title":"Thromb Res"},{"issue":"12","key":"10.1111\/jth.15082_bb0185","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood-2012-10-460493","article-title":"Rapid activation of monocyte tissue factor by antithymocyte globulin is dependent on complement and protein disulfide isomerase","volume":"121","author":"Langer","year":"2013","journal-title":"Blood"},{"issue":"14","key":"10.1111\/jth.15082_bb0190","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1182\/blood.2019001530","article-title":"Tissue factor pathway inhibitor primes monocytes for antiphospholipid antibody\u2010induced thrombosis","volume":"134","author":"Muller\u2010Calleja","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1111\/jth.15082_bb0195","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1182\/bloodadvances.2018017095","article-title":"Complement C5 but not C3 is expendable for tissue factor activation by cofactor\u2010independent antiphospholipid antibodies","volume":"2","author":"Muller\u2010Calleja","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"10.1111\/jth.15082_bb0200","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/art.21549","volume":"54","author":"Lopez\u2010Pedrera","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"31","key":"10.1111\/jth.15082_bb0205","doi-asserted-by":"crossref","first-page":"14587","DOI":"10.1016\/S0021-9258(18)66911-X","article-title":"On the mechanism by which complement proteins C5b\u20139 increase platelet prothrombinase activity","volume":"261","author":"Wiedmer","year":"1986","journal-title":"J Biol Chem"},{"issue":"16","key":"10.1111\/jth.15082_bb0210","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1182\/blood-2016-11-749879","article-title":"Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development","volume":"129","author":"Subramaniam","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1111\/jth.15082_bb0215","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/j.1538-7836.2009.03334.x","article-title":"Abnormal platelet function in C3\u2010deficient mice","volume":"7","author":"Gushiken","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"16","key":"10.1111\/jth.15082_bb0220","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1161\/CIRCULATIONAHA.118.034600","article-title":"Functional relevance of the anaphylatoxin receptor C3aR for platelet function and arterial thrombus formation marks an intersection point between innate immunity and thrombosis","volume":"138","author":"Sauter","year":"2018","journal-title":"Circulation"},{"issue":"4","key":"10.1111\/jth.15082_bb0225","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.blre.2017.02.003","article-title":"Complementopathies","volume":"31","author":"Baines","year":"2017","journal-title":"Blood Rev"},{"issue":"6","key":"10.1111\/jth.15082_bb0230","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99128","article-title":"Germline mutations in the alternative pathway of complement predispose to HELLP syndrome","volume":"3","author":"Vaught","year":"2018","journal-title":"JCI Insight"},{"issue":"4","key":"10.1111\/jth.15082_bb0235","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux\u2010Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1111\/jth.15082_bb0240","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1111\/jth.15082_bb0245","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.autrev.2014.03.002","article-title":"14th international congress on antiphospholipid antibodies task force report on catastrophic antiphospholipid syndrome","volume":"13","author":"Cervera","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"1 Pt 1","key":"10.1111\/jth.15082_bb0250","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0002-9378(11)90700-5","article-title":"Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB\/c mice: a model for autoimmune fetal loss","volume":"163","author":"Branch","year":"1990","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1111\/jth.15082_bb0255","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1084\/jem.200116116","article-title":"Complement C3 activation is required for antiphospholipid antibody\u2010induced fetal loss","volume":"195","author":"Holers","year":"2002","journal-title":"J Exp Med"},{"issue":"10","key":"10.1111\/jth.15082_bb0260","first-page":"3453","article-title":"Neutrophil activation by the tissue factor\/Factor VIIa\/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome","volume":"118","author":"Redecha","year":"2008","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1111\/jth.15082_bb0265","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.molimm.2004.07.043","article-title":"A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody\u2010induced pregnancy loss in mice","volume":"42","author":"Thurman","year":"2005","journal-title":"Mol Immunol"},{"key":"10.1111\/jth.15082_bb0270","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1196\/annals.1361.083","article-title":"Complement activation: a novel pathogenic mechanism in the antiphospholipid syndrome","volume":"1051","author":"Pierangeli","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"10.1111\/jth.15082_bb0275","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1084\/jem.182.6.1807","article-title":"Complement\u2010mediated regulation of tissue factor activity in endothelium","volume":"182","author":"Saadi","year":"1995","journal-title":"J Exp Med"},{"issue":"2","key":"10.1111\/jth.15082_bb0280","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1191\/0961203305lu2048oa","article-title":"Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies","volume":"14","author":"Forastiero","year":"2005","journal-title":"Lupus"},{"issue":"2","key":"10.1111\/jth.15082_bb0285","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1055\/s-0037-1615676","article-title":"Plasma tumor necrosis factor alpha levels and the \u2010238*A promoter polymorphism in patients with antiphospholipid syndrome","volume":"85","author":"Bertolaccini","year":"2001","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1111\/jth.15082_bb0290","first-page":"503","article-title":"IL\u20102, IL\u20106 and TNF levels in primary antiphospholipid syndrome","volume":"10","author":"Ahmed","year":"1992","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1111\/jth.15082_bb0295","first-page":"455","article-title":"Antiphospholipid antibodies and complement activation in patients with cerebral ischemia","volume":"10","author":"Davis","year":"1992","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1111\/jth.15082_bb0300","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/ard.2008.090670","article-title":"Complement activation in patients with primary antiphospholipid syndrome","volume":"68","author":"Oku","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1111\/jth.15082_bb0305","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1160\/TH11-08-0554","article-title":"Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome","volume":"107","author":"Breen","year":"2012","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1111\/jth.15082_bb0310","first-page":"1279","article-title":"Is there an association between complement activation and antiphospholipid antibody\u2010related thrombosis?","volume":"104","author":"Devreese","year":"2010","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1111\/jth.15082_bb0315","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/blood-2015-09-672139","article-title":"Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery","volume":"127","author":"Meroni","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1111\/jth.15082_bb0320","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.exphem.2016.01.005","article-title":"Direct evidence of complement activation in HELLP syndrome: a link to atypical hemolytic uremic syndrome","volume":"44","author":"Vaught","year":"2016","journal-title":"Exp Hematol"},{"issue":"7","key":"10.1111\/jth.15082_bb0325","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/jmg.2008.064766","article-title":"The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome","volume":"46","author":"Dragon\u2010Durey","year":"2009","journal-title":"J Med Genet"},{"issue":"12","key":"10.1111\/jth.15082_bb0330","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1182\/blood-2009-02-205641","article-title":"Factor H\u2010related protein 1 (CFHR\u20101) inhibits complement C5 convertase activity and terminal complex formation","volume":"114","author":"Heinen","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1111\/jth.15082_bb0335","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1073\/pnas.1219260110","article-title":"Dimerization of complement factor H\u2010related proteins modulates complement activation in vivo","volume":"110","author":"Goicoechea de Jorge","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1111\/jth.15082_bb0340","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.molimm.2015.07.016","article-title":"Role of complement receptor 1 (CR1; CD35) on epithelial cells: a model for understanding complement\u2010mediated damage in the kidney","volume":"67","author":"Java","year":"2015","journal-title":"Mol Immunol"},{"issue":"6","key":"10.1111\/jth.15082_bb0345","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10\u2010year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1111\/jth.15082_bb0350","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical course of high\u2010risk patients diagnosed with antiphospholipid syndrome","volume":"8","author":"Pengo","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1111\/jth.15082_bb0355","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study","volume":"133","author":"Lee","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1111\/jth.15082_bb0360","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.12347","article-title":"Long\u2010term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria","volume":"162","author":"Hillmen","year":"2013","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1111\/jth.15082_bb0365","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/ajt.12540","article-title":"Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation","volume":"14","author":"Lonze","year":"2014","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1111\/jth.15082_bb0370","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/0961203320917460","article-title":"Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature","volume":"29","author":"Skoczynska","year":"2020","journal-title":"Lupus"},{"issue":"8","key":"10.1111\/jth.15082_bb0375","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/art.34440","article-title":"Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab","volume":"64","author":"Shapira","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1111\/jth.15082_bb0380","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/rheumatology\/kev371","article-title":"A case of relapsing and refractory catastrophic anti\u2010phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor","volume":"55","author":"Wig","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1111\/jth.15082_bb0385","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/RHU.0000000000000290","article-title":"Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome","volume":"21","author":"Zikos","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"10.1111\/jth.15082_bb0390","first-page":"704371","article-title":"36\u2010year\u2010old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature","volume":"2014","author":"Strakhan","year":"2014","journal-title":"Case Rep Hematol"},{"issue":"40","key":"10.1111\/jth.15082_bb0395","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012584","article-title":"Eculizumab in a pregnant patient with laboratory onset of catastrophic antiphospholipid syndrome: a case report","volume":"97","author":"Rovere\u2010Querini","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"10.1111\/jth.15082_bb0400","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006338","article-title":"Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome: a case report","volume":"96","author":"Gustavsen","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1111\/jth.15082_bb0405","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/qjmed\/hcv082","article-title":"A national specialized service in England for atypical haemolytic uraemic syndrome\u2010the first year's experience","volume":"109","author":"Sheerin","year":"2016","journal-title":"QJM"},{"issue":"4","key":"10.1111\/jth.15082_bb0410","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","article-title":"Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases","volume":"64","author":"Ardissino","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1111\/jth.15082_bb0415","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1053\/j.ajkd.2014.04.039","article-title":"Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome","volume":"65","author":"Wetzels","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1111\/jth.15082_bb0420","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood-2017-02-770214","article-title":"Eculizumab cessation in atypical hemolytic uremic syndrome","volume":"130","author":"Merrill","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1111\/jth.15082_bb0425","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.semarthrit.2011.05.007","article-title":"HELLP syndrome and its relationship with antiphospholipid syndrome and antiphospholipid antibodies","volume":"41","author":"Appenzeller","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1111\/jth.15082_bb0430","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.placenta.2012.11.014","article-title":"Eculizumab for the treatment of preeclampsia\/HELLP syndrome","volume":"34","author":"Burwick","year":"2013","journal-title":"Placenta"},{"issue":"6","key":"10.1111\/jth.15082_bb0435","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1161\/HYPERTENSIONAHA.113.01420","article-title":"Urinary excretion of C5b\u20139 in severe preeclampsia: tipping the balance of complement activation in pregnancy","volume":"62","author":"Burwick","year":"2013","journal-title":"Hypertension"},{"issue":"4","key":"10.1111\/jth.15082_bb0440","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.imbio.2014.11.003","article-title":"Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn","volume":"220","author":"Hallstensen","year":"2015","journal-title":"Immunobiology"},{"issue":"23","key":"10.1111\/jth.15082_bb0445","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood.2020006000","article-title":"COVID\u201019 and its implications for thrombosis and anticoagulation","volume":"135","author":"Connors","year":"2020","journal-title":"Blood"},{"key":"10.1111\/jth.15082_bb0450","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.thromres.2020.04.024","article-title":"Venous and arterial thromboembolic complications in COVID\u201019 patients admitted to an academic hospital in Milan, Italy","volume":"191","author":"Lodigiani","year":"2020","journal-title":"Thromb Res"},{"issue":"5","key":"10.1111\/jth.15082_bb0455","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jtho.2020.02.010","article-title":"Pulmonary pathology of early\u2010phase 2019 Novel Coronavirus (COVID\u201019) pneumonia in two patients with lung cancer","volume":"15","author":"Tian","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1111\/jth.15082_bb0460","doi-asserted-by":"crossref","first-page":"e01753","DOI":"10.1128\/mBio.01753-18","article-title":"Complement activation contributes to severe acute respiratory syndrome Coronavirus pathogenesis","volume":"9","author":"Gralinski","year":"2018","journal-title":"MBio"},{"issue":"10","key":"10.1111\/jth.15082_bb0465","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1086\/429631","article-title":"Mannose\u2010binding lectin in severe acute respiratory syndrome coronavirus infection","volume":"191","author":"Ip","year":"2005","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1111\/jth.15082_bb0470","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1373\/clinchem.2005.061689","article-title":"Serum proteomic fingerprints of adult patients with severe acute respiratory syndrome","volume":"52","author":"Pang","year":"2006","journal-title":"Clin Chem"},{"issue":"7","key":"10.1111\/jth.15082_bb0475","first-page":"4040","article-title":"Eculizumab treatment in patients with COVID\u201019: preliminary results from real life ASL Napoli 2 Nord experience","volume":"24","author":"Diurno","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"17","key":"10.1111\/jth.15082_bb0480","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2007575","article-title":"Coagulopathy and antiphospholipid antibodies in patients with Covid\u201019","volume":"382","author":"Zhang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15082_bb0485","article-title":"Lupus anticoagulant is frequent in patients with Covid\u201019","author":"Harzallah","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1111\/jth.15082_bb0490","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1053\/sarh.2002.28303","article-title":"Viral infections and antiphospholipid antibodies","volume":"31","author":"Uthman","year":"2002","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1111\/jth.15082_bb0495","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11926-007-0034-x","article-title":"Antiphospholipid antibodies in response to infection","volume":"9","author":"Avcin","year":"2007","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"10.1111\/jth.15082_bb0500","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/ard.62.5.388","article-title":"Antiphospholipid antibodies and infections","volume":"62","author":"Asherson","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1111\/jth.15082_bb0505","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.thromres.2009.09.001","article-title":"Lupus anticoagulant (LAC) testing in patients with inflammatory status: does C\u2010reactive protein interfere with LAC test results?","volume":"125","author":"Schouwers","year":"2010","journal-title":"Thromb Res"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15082","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.15082","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622006717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622006717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:32:17Z","timestamp":1761535937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622006717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1538783622006717"],"URL":"https:\/\/doi.org\/10.1111\/jth.15082","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.15082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}